Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity

Apostolidis, Apostolos; Jacques, Thomas S.; Freeman, Alex; Kalsi, Vinay; Popat, Roshni; Gonzales, Gwen; Datta, Shubhashis; Ghazi-Noori, Shabnam; Elneil, Sohier; Dasgupta, Prokar; Fowler, Clare J.

doi:10.1016/j.eururo.2008.02.037

Cited by 144 publications

(109 citation statements)

References 32 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…17 Biopsies in patients undergoing repeated injections have failed to demonstrate a significant association with inflammation or dysplasia. 18 Although experience with BTX-A has accumulated, questions remain around the optimal volume and number of injections, and the place of trigonal injections. …”

Section: Botulinum Toxin Amentioning

confidence: 99%

The overactive bladder: where are we in 2016?

Osman

Chapple

2016

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

Section: Botulinum Toxin Amentioning

confidence: 99%

The overactive bladder: where are we in 2016?

Osman

Chapple

2016

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

“…Аргументацией этой теории является нали-чие хронических изменений, сформировавшихся на фоне перенесенного воспаления, в гистологических образцах при биопсии мочевого пузыря у пациентов с ГМП [16,17]. P. Tyagi и соавт.…”

Section: мочевые биомаркерыunclassified

Novelty in the diagnosis of overactive bladder

Amirova¹,

Балан²,

Kovaleva³

et al. 2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Увеличение продолжительности жизни населения влечет за собой повышение частоты развития заболева-ний, ассоциированных с возрастом, в том числе гиперак-тивного мочевого пузыря (ГМП). По данным последних эпидемиологических исследований, распространенность симптомов ГМП составляет 7-27% среди мужчин и 9-43% среди женщин [1].Показано, что частота развития ГМП у женщин со-ставляет 20-30% в репродуктивном возрасте, 30-40% в перименопаузе и ранней постменопаузе, а в пожилом воз-расте достигает 50%. Установлено, что пациенты редко обращаются за медицинской помощью, а среди обратив-шихся только 2% получают адекватную терапию [2]. «Золотым стандартом» в диагностике ГМП и гипер-активности детрузора является комплексное уродинами-ческое исследование, однако инвазивность, трудоем-кость и дороговизна метода зачастую являются прегра-дой для масштабного скрининга населения с целью улуч-шения качества доступной медицинской помощи. Со-временные исследования посвящены определению воз-можностей использования неинвазивных биомаркеров для выявления симптомов ГМП, оценки эффективности лечения и прогнозирования исхода заболевания. Подоб-ные методики включают ультразвуковую оценку толщи-ны стенки мочевого пузыря и толщины детрузора, опре-деление параметров сывороточных (С-реактивный бе-

show abstract

“…58 NGF levels in the bladder tissue increased significantly in patients with BPS/IC, and decreased to the normal range after botulinum toxin A treatment. 79 However, urine NGF is also increased in several lower urinary tract conditions, such as urinary tract infection, bladder outlet obstruction and urinary tract stones. 57 The clinical symptoms of BPS/IC and OAB are similar, but bladder pain is typically found in BPS/IC, and urgency/urgency incontinence is found in OAB.…”

Section: Urinary Nerve Growth Factor and Inflammatory Markersmentioning

confidence: 99%

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

Kuo

2014

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms APF = antiproliferative factor BPS/IC = bladder pain syndrome/interstitial cystitis BUC = bladder urothelial cells CRP = C-reactive protein EGF = epidermal growth factor GP51 = glycoprotein 51 HB-EGF = heparin binding growth factor-like growth factor IC = interstitial cystitis IL = interleukin MCP-1 = monocyte chemotactic protein-1 MIP-1β = macrophage inflammatory protein OAB = overactive bladder NGF = nerve growth factor NIDDK = National Institute of Diabetes, Digestive, and Kidney Diseases TNF-α = tumor necrosis factor-α ZO-1 = zonula occludens-1 Abstract: There is a lack of consensus on the pathophysiology of bladder pain syndrome/ interstitial cystitis. The chronic pain symptoms of bladder pain syndrome/interstitial cystitis refractory to local treatment could be a result of central nervous system sensitization and persisting abnormalities in the bladder wall, which activate the afferent sensory system. Evidence also shows that bladder pain syndrome/interstitial cystitis is a heterogeneous syndrome and that the two subtypes, the ulcerative (classic) and non-ulcerative types, represent different disease entities. There is a need for non-invasive markers for the differential diagnoses of the subtypes of bladder pain syndrome/interstitial cystitis, and between bladder pain syndrome/interstitial cystitis and bladder sensory disorders, such as hypersensitive bladder syndrome or overactive bladder. Bladder pain syndrome/interstitial cystitis, but not overactive bladder, involves an aberrant differentiation program in the bladder urothelium that leads to altered synthesis of several proteoglycans, cell adhesion and tight junction proteins, and bacterial defense molecules. These findings have led to the rationale for identifying urinary biomarkers to detect bladder pain syndrome/interstitial cystitis in patients with frequency urgency syndrome. Recently, the markers that have been the focus of the most research are antiproliferative factor, epidermal growth factor, heparin-binding epidermal growth factor, glycosaminoglycans and bladder nitric oxide. In addition, inflammatory proteins in the urine and serum play important roles in the pathogenesis of bladder pain syndrome/interstitial cystitis. The urinary proteome is an easily accessible source of biomarkers for differentiation between inflammatory bladder disorders. Analysis of multiple urinary proteins and serum cytokines could provide a diagnostic basis for bladder pain syndrome/interstitial cystitis, and could be a tool for the differential diagnosis of bladder pain syndrome/interstitial cystitis and other sensory bladder disorders.

show abstract

Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity

Cited by 144 publications

References 32 publications

The overactive bladder: where are we in 2016?

The overactive bladder: where are we in 2016?

Novelty in the diagnosis of overactive bladder

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

Contact Info

Product

Resources

About